newsfilter
← Earnings
Earnings Releases·

Cronos Group — Third Quarter 2026 Earnings Summary

  • Net revenue for Q3 2026 reached $63.45 million, a 75% year-over-year increase, while Adjusted EBITDA surged 201% YoY to $17.08 million; for the nine-month period, net income turned positive at $69.20 million compared to a $2.44 million loss in the prior period.
  • The company maintained an industry-leading balance sheet with $840.63 million in liquid assets and generated positive operating cash flow for the first nine months of 2026, supporting a share repurchase program that bought back 15.5 million shares for $42.3 million year-to-date.
  • Strategic growth is being driven by the ongoing integration of the CanAdelaar acquisition to expand in the Netherlands and record-breaking performance in international markets, which saw a 614% YoY revenue increase led by German flower demand.
  • Management highlighted strong market share retention for the Spinach® brand in Canada and confirmed a continued focus on borderless products, while noting ongoing risks related to Israeli anti-dumping investigations and Middle East geopolitical instability.
Company
CRONOS GROUP INC
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic